insights_auto
Nega OPHLY oshdi 5,91%?
Batafsil oʻrganishchevron_right
OPHLY:OTCMKTS
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
4,92Â US$
arrow_upward
+5,91%(+0,28) 1K
15-okt, 16:00:00 (GMT-4) · USD
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoOPHLY tikeri uchun statistika yaratilmoqda...
Ochish
4,96Â US$
Yuqori
4,96Â US$
Past
4,90Â US$
Bozor kapitali
1,20Â trln
Oʻrtacha hajm
61,54Â ming
Hajmi
68,37Â ming
52 haftalik eng yuqori
5,75Â US$
52 haftalik eng past
3,82Â US$
Beta
0,21
Muomaladagi aksiyalar
1,50Â mlrd
Xodimlar soni
4Â ming
Ochish
4,96Â US$
Yuqori
4,96Â US$
Past
4,90Â US$
Bozor kapitali
1,20Â trln
Oʻrtacha hajm
61,54Â ming
Hajmi
68,37Â ming
52 haftalik eng yuqori
5,75Â US$
52 haftalik eng past
3,82Â US$
Beta
0,21
Muomaladagi aksiyalar
1,50Â mlrd
Xodimlar soni
4Â ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
The Daily News | Texas' Oldest Newspaper
·
8 daqiqa oldin
FILE PHOTO: Signage is seen outside the New York Stock Exchange (NYSE) in Manhattan, New York City
Stock Titan
·
41 daqiqa oldin
32 new hires get awards tied to 57,853 shares, but vesting depends on continued employment.
American Ag Network
·
35 daqiqa oldin
NYSE Owner Challenges CME in Livestock Futures Market
Yahoo Finance
·
47 daqiqa oldin
1 Nasdaq 100 Stock on Our Watchlist and 2 That Underwhelm
Profil
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs haqida
CEOGyo Sagara | Gyo Sagara
Xodimlar soni4,21Â ming
Asos solingan1717
Bosh ofislarOsaka, Osaka, Yaponiya
Sektor-
Veb-saytono-pharma.com